Genus PLC Accelerates $160M Chinese Porcine Joint Venture with BCA

Putting PIC China under a domestic state-backed partner (BCA) is, in Genus’s words, “the best possible route” to MARA approval. That matters because PRP is potentially transformative for productivity, animal health, and costs in China’s massive pork market.

Financial reporting impact: deconsolidation and capital allocation

Post-completion, PIC China will be deconsolidated from Genus’s financials. Instead, Genus’s 49% stake will be equity accounted – so expect lower reported revenue, but an ongoing share of profit plus China PRP royalties and dividends if and when commercialisation hits scale.

Management intends to use proceeds for balance sheet deleveraging and potential additional shareholder returns, consistent with its capital allocation framework. The precise form and timing of any extra returns are not disclosed.

Valuation context: cash versus book value and PIC China’s current scale

As at 30 June 2025, the total book value of net assets attributable to PIC China was approximately £32m. In the twelve months to 30 June 2025, revenue of £41.3m and adjusted operating profit including joint ventures of £8.4m were attributable to PIC China.

Set against that, the US$160m gross payment and US$7.5m milestone look like a material crystallisation of value ahead of PRP approval. Genus gives up control, but keeps a 49% stake plus future royalties and dividends – providing ongoing economic exposure if PRP scales in China.

What to watch from here

• Regulatory approvals: the JV formation needs sign-off from the relevant Chinese state-owned assets authority; PRP commercialisation requires MARA approval.
• Timing: Stage 1 targeted for FY26; Stage 2 during 2026; full completion expected in 2026.
• Cash receipt: US$160m gross and US$7.5m milestone tied to Stage 1 completion and approval conditions.
• Working capital/net debt adjustments: these could tweak the net cash received.
• Royalty detail: rates and mechanics are “consistent with the original agreements”, but not disclosed publicly.
• Financial presentation: watch for deconsolidation impacts on reported revenue and operating profit once the JV completes, with a shift to equity-accounted earnings.
• Capital allocation: management flags deleveraging first, with potential additional shareholder returns thereafter.

Josh’s take: a pragmatic China pivot with upfront cash and retained upside

On balance, this is a tidy piece of de-risking. Genus secures substantial upfront cash, aligns PIC China more tightly with a state-backed partner, and preserves the long-term economics of PRP through royalties and a 49% equity stake. For a programme where regulatory access is make-or-break, that’s sensible.

The flip side: Genus gives up control of PIC China and will deconsolidate the unit, which will likely reduce reported revenue once the deal closes. The full benefits still hinge on MARA approvals and successful PRP roll-out, which are not guaranteed. But the cash inflow – especially versus PIC China’s £32m book value – and the clearer route to market in the world’s largest pork economy make this a strategically positive move.

Jargon buster

• PRRS: Porcine Reproductive and Respiratory Syndrome, a virus that hits pig health and productivity.
• PRP: PRRS Resistant Pig – Genus’s gene-edited pig line designed to resist PRRS.
• MARA: China’s Ministry of Agriculture and Rural Affairs, the key regulator for agricultural biotech approvals.
• Deconsolidated: The business no longer sits within Genus’s consolidated revenue and profit; instead, Genus records its share of profits below the line.
• Equity accounted: Genus recognises its 49% share of the JV’s profit rather than consolidating 100% of revenue and cost lines.
• Withholding tax: Tax deducted at source in a cross-border payment before funds are remitted.